Journal of Neural Transmission

, Volume 120, Issue 10, pp 1447–1451

Atrial fibrillation and stroke prevention: is warfarin still an option? Yes

Debate at the Controversies in Neurology congress, Beijing October 2011
Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Abstract

With the advent of new oral anticoagulants, the place of warfarin for stroke prevention in patients with atrial fibrillation needs re-evaluation. Warfarin is difficult to use, because of large individual differences in response and metabolism, many significant interactions with drugs and foods, and fluctuations in vitamin K absorption. It requires frequent blood testing and dose adjustments, so with good reason patients and physicians are eager for the newer agents that are easier to use. However, the purchase price of the new anticoagulants is so high that warfarin will remain in widespread use. It is important therefore for physicians to know how to use it well. Anticoagulants work much better for stroke prevention in atrial fibrillation than do antiplatelet agents; physicians need to understand the concept of red thrombus (for which anticoagulants are required) versus white thrombus—platelet aggregates—which are the target of antiplatelet agents. Stroke from atrial fibrillation increases steeply with age, and the elderly benefit disproportionately from anticoagulation. It is still necessary for physicians to know how to use warfarin, and to use it better than it has been used in the past.

Keywords

Atrial fibrillation Stroke prevention Warfarin New oral anticoagulants Vitamin B12 

References

  1. Boston Collaborative Drug Surveillance Program (1972) Interaction between chloral hydrate and warfarin. A report from the Boston Collaborative Drug Surveillance Program, Boston Universtiy Medical Center. N Engl J Med 286:53–55. doi:10.1056/NEJM197201132860201 Google Scholar
  2. Bang H, Mazumdar M, Spence JD (2006) Tutorial in biostatistics: analyzing associations between total plasma homocysteine and B vitamins using optimal categorization and segmented regression. Neuroepidemiology 27:188–200PubMedCrossRefGoogle Scholar
  3. Caplan LR, Fisher M (2007) The endothelium, platelets, and brain ischemia. Rev Neurol Dis 4:113–121PubMedGoogle Scholar
  4. Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG (2011) Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. Ann Intern Med 155:579–586. doi:10.1059/0003-4819-155-9-201111010-00004 PubMedCrossRefGoogle Scholar
  5. del Zoppo GJ, Eliasziw M (2011) New options in anticoagulation for atrial fibrillation. N Engl J Med 365:952–953. doi:10.1056/NEJMe1107516 PubMedCrossRefGoogle Scholar
  6. Deykin D (1967) Thrombogenesis. N Engl J Med 276:622–628PubMedCrossRefGoogle Scholar
  7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579. doi:10.1161/CIRCULATIONAHA.111.029017 PubMedCrossRefGoogle Scholar
  8. Fisher CM (1959) Observations of the fundus oculi in transient monocular blindness. Neurology 9:333–347PubMedCrossRefGoogle Scholar
  9. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240PubMedCrossRefGoogle Scholar
  10. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106. doi:10.1001/archinte.165.10.1095 PubMedCrossRefGoogle Scholar
  11. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303:1603–1609. doi:10.1001/jama.2010.490 PubMedCrossRefGoogle Scholar
  12. Hylek EM, Frison L, Henault LE, Cupples A (2008) Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 39:3009–3014PubMedCrossRefGoogle Scholar
  13. Juurlink DN (2007) Drug interactions with warfarin: what clinicians need to know. CMAJ 177:369–371PubMedGoogle Scholar
  14. Man-Son-Hing M, Nichol G, Lau A, Laupacis A (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159:677–685PubMedCrossRefGoogle Scholar
  15. Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, Lenti M, Gensini GF, Abbate R, Prisco D (2005) Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 36:2159–2163PubMedCrossRefGoogle Scholar
  16. Rombouts EK, Rosendaal FR, Van Der Meer FJ (2007a) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048PubMedCrossRefGoogle Scholar
  17. Rombouts EK, Rosendaal FR, van der Meer FJ (2007b) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048PubMedCrossRefGoogle Scholar
  18. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J (2000) Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 160:967–973PubMedCrossRefGoogle Scholar
  19. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008PubMedCrossRefGoogle Scholar
  20. Sellers EM, Koch-Weser J (1970) Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med 283:827–831. doi:10.1056/NEJM197010152831601 PubMedCrossRefGoogle Scholar
  21. Sellers EM, Koch-Weser J (1971) Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci 179:213–225PubMedCrossRefGoogle Scholar
  22. Spence JD (2006) Nutrition and stroke prevention. Stroke 37:2430–2435PubMedCrossRefGoogle Scholar
  23. Spence JD (2007) Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 7:830–838CrossRefGoogle Scholar
  24. Spence D (2009a) Mechanisms of thrombogenesis in atrial fibrillation. Lancet 373:1006–1007PubMedCrossRefGoogle Scholar
  25. Spence JD (2009b) Stroke: atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol 6:448–450PubMedCrossRefGoogle Scholar
  26. Spence JD, Stampfer MJ (2011) Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 306(23):2610–2611Google Scholar
  27. Spence JD, Bang H, Chambless LE, Stampfer MJ (2005) Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 36:2404–2409PubMedCrossRefGoogle Scholar
  28. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127. doi:10.1160/TH09-11-0758 PubMedCrossRefGoogle Scholar
  29. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE (2009) Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40:1410–1416. doi:10.1161/STROKEAHA.108.526988 PubMedCrossRefGoogle Scholar
  30. Vogiatzoglou A, Oulhaj A, Smith AD, Nurk E, Drevon CA, Ueland PM, Vollset SE, Tell GS, Refsum H (2009) Determinants of plasma methylmalonic acid in a large population: implications for assessment of vitamin B12 status. Clin Chem 55:2198–2206PubMedCrossRefGoogle Scholar
  31. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western OntarioLondonCanada

Personalised recommendations